Cellular Therapies Carry Notable Infection Risks

Preliminary data show infections in 43% of patients with autoimmune disease treated with these therapies.

Updated on Nov. 8, 2026 in Arthritis

Isometric editorial illustration of three plain amber glass vials on a cream surface, one holding cloudy liquid, with a curved clear tube at the base.
Infections occurred in 43% of autoimmune patients treated with cellular therapies, according to preliminary findings presented at the ACR Convergence meeting in Orlando. AI Illustration. Upload story photo >

Preliminary findings from a systematic review presented at the ACR Convergence meeting in Orlando suggest that infections and low antibody levels are common after cellular therapies used in immune-mediated inflammatory disease. The review drew on 25 studies covering 15 autoimmune diseases and 16 treatments, with infections reported in 43% of evaluable patients.

Why it matters

Cellular therapies such as CAR T-cell treatments and T-cell engagers are being explored for autoimmune conditions, and this review suggests their infectious and immune-related side effects are still incompletely defined. Clearer data on which therapies carry the greatest infection risk can help clinicians and patients weigh benefits against those risks.

This preliminary systematic review screened 10,971 studies and analyzed 25 of them from China, Germany, Spain and the United States. The results come from a small, heterogeneous evidence base, and no fatalities were reported among 65 patients evaluable for outcome.

The players

American College of Rheumatology (ACR)

The ACR is the professional society for rheumatologists and sponsors the ACR Convergence meeting, where research on autoimmune and inflammatory diseases is presented.

Cleveland Clinic

Cleveland Clinic is a major academic medical center whose researchers contribute to clinical work on autoimmune disease and cellular therapies.

The details

CAR T-cell therapies and T-cell engagers work by reprogramming or redirecting immune cells to target disease-causing cells, which can also weaken broader immune defenses. In this review, low antibody levels, known as hypogammaglobulinemia, were common and about half of affected patients received immunoglobulin replacement. Infection rates varied by therapy, with CD19 CAR T cells at 45%, BCMA CAR T cells at 57%, dual-target CD19/BCMA CAR-T at 46%, and CAR-natural killer therapies at 6%.

Timeline

  1. Eligible studies were published on or after Aug. 5, 2021, the earliest date for inclusion in the review.

  2. The preliminary findings were presented at ACR Convergence in Orlando on Nov. 8, 2026.

Health Landscape

CAR T-cell therapies were developed and approved first for blood cancers, and their use is now being explored in autoimmune conditions such as lupus and rheumatoid arthritis. This review adds a preliminary safety picture showing that infection and antibody deficiency patterns seen in cancer patients also appear in immune-mediated disease.

If you have an autoimmune condition and are considering a cellular therapy, it is worth asking your rheumatologist about infection risk, antibody testing and prevention strategies. Reporting new fevers or unusual infections promptly to your care team is a sensible habit while these therapies are still being studied.

The takeaway

Infections and low antibody levels appear to be meaningful side effects of cellular therapies in autoimmune disease, though these findings are preliminary. Patients considering these treatments should discuss infection prevention and monitoring plans with their physician.

Further reading

For more background on treatments and research in this area, explore the Arthritis section.